Mayo Clinic wins FDA approval to test stem-cell heart therapy

by Dan Browning

A decade-long Mayo Clinic research project on using stem cells to repair damaged heart tissue has won federal approval for human testing, a step that could have implications for millions of Americans with heart disease.

The U.S. Food and Drug Administration has approved a multistate clinical trial of 240 patients with chronic advanced symptomatic heart failure to see if the new procedure produces a significant improvement in heart function, Mayo officials announced Friday.

Safety testing in humans, completed earlier in Europe, showed a preliminary 25 percent improvement in cardiac outflow, according to Dr. Andre Terzic, director of the Mayo Clinic's Center for Regenerative Medicine.

The procedure could be a "paradigm shift" in the treatment of heart disease, Terzic said.

Going forward, he said, treatments won't just focus on easing the symptoms of , but rather on curing it.

The process, developed in collaboration with Cardio3 BioSciences of Belgium, involves harvesting stem cells from a patient's bone marrow in the hip, directing the cells to become "cardiopoietic" repair cells, then injecting them back into the heart to do their work.

Mayo researcher Dr. Atta Behfar and other members of Terzic's team isolated hundreds of proteins involved in the "transcription" process that takes place when stem cells are converted to . They identified eight proteins that were crucial, and used them to convert into cells.

"This is unique in the world," Terzic said.

Dr. Ganesh Raveendran, a cardiologist and co-director of the University of Minnesota's cardiac cell therapy program, called the Mayo research encouraging, but advised caution. Raveendran said a variety of small stem cell studies have shown mixed results, but when the treatments were tested in larger studies, they showed no beneficial effects. "We need to wait and see," he said.

For now, 40 hospitals in Europe and Israel are enrolling patients in human trials to test the Mayo procedure. Enrollments are expected to be completed by the end of the year, and early results should be available in 2015, according to Dr. Christian Homsy, CEO of Cardio3 BioSciences.

If things go well, patients in Europe could start being treated with the new technology by the end of 2016, and perhaps a year later for patients in the United States.

Homsy said more than $110 million has been spent in Europe developing and testing the process, and that he expects his company to increase its presence in Rochester, Minn., to work more closely with Mayo researchers there.

"Our collaboration with Mayo has been so productive that we have many, many opportunities that we'd like to explore," Homsy said.

Mayo researchers are working on similar "" projects involving many other ailments, including diabetes, diseases of the liver and lungs, neurological disorders and orthopedics, Terzic said.

"Cardiovascular disease may be the beginning of a ... a magnificent journey of addressing various diseases that humankind is confronting, especially with the aging of the population," he said.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New way to weed out problem stem cells, making therapy safer

Sep 27, 2012

Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult ...

Recommended for you

An autoimmune response may contribute to hypertension

12 hours ago

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

Results of RIBS IV trial reported

Sep 16, 2014

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

Sep 16, 2014

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

Results of IVUS-CTO trial reported at TCT 2014

Sep 16, 2014

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous ...

User comments